论文部分内容阅读
[目的]结合临床实践经验,探讨紫杉醇联合卡铂治疗卵巢癌的临床疗效。[方法]选取我院卵巢癌的患者58例为研究对象,行肿瘤细胞减灭术进行紫杉醇联合卡铂的化疗治疗,共6个疗程。疗程结束后,对疗效以及患者的不良效果进行总结分析。[结果]化疗后,平均见效时间为15 d,。本次研究中,总体有效率为74.14%。其中,Ⅲ期有效率为71.79%,Ⅳ期有效率为52%,两者之间差异无统计学意义;残留灶≤2 cm者有效率为73.91,残留灶﹥2cm者50.00%,两者差异有统计学意义(P﹤0.05),提示残留灶≤2 cm者疗效优于残留灶﹥2 cm者。所有患者在接受化疗期间,无过敏反应发生。脱发与白细胞减少的发生率较高,对患者进行粒细胞集落刺激因子治疗后恢复正常。消化道反应、肌肉酸痛、水肿等反应的发生情况,与相关文献报道基本一致。[结论]紫杉醇联合卡铂是全球广泛用于卵巢癌的一线化疗方案,其患者依从性好,胃肠道反应小,疗效肯定,值得临床推广使用。
[Objective] To explore the clinical efficacy of paclitaxel combined with carboplatin in the treatment of ovarian cancer. [Method] Fifty-eight patients with ovarian cancer in our hospital were selected as the research object. Chemotherapy of paclitaxel combined with carboplatin was performed in tumor cytoreductive surgery for a total of 6 courses. After the course of treatment, the curative effect and the adverse effect of the patient are summarized and analyzed. [Results] After chemotherapy, the average effective time was 15 days. In this study, the overall effective rate was 74.14%. Among them, the effective rate was 71.79% in stage Ⅲ and 52% in stage Ⅳ, the difference was not statistically significant; the effective rate was 73.91 in residual lesions ≤ 2 cm and 50.00% in residual lesions> 2 cm There was statistical significance (P <0.05), suggesting that residual lesions ≤ 2 cm were better than residual lesions> 2 cm. No allergic reaction occurred during chemotherapy in all patients. The incidence of alopecia and leukopenia is high, and the patient returns to normal after treatment with granulocyte-colony stimulating factor. Gastrointestinal reactions, muscle soreness, edema and other reactions occurred, and the relevant literature reported basically the same. [Conclusion] Paclitaxel combined with carboplatin is the first-line chemotherapy widely used in ovarian cancer in the world. Its compliance is good, gastrointestinal reaction is small, and the curative effect is definite. It is worth to be used clinically.